Insmed Incorporated (NASDAQ:INSM) CFO Sells $1,471,439.82 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 18,322 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, February 11th, Sara Bonstein sold 13,302 shares of Insmed stock. The shares were sold at an average price of $80.00, for a total value of $1,064,160.00.
• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total value of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total value of $227,979.00.

Insmed Trading Down 3.0 %

Shares of Insmed stock opened at $81.06 on Friday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock’s 50-day simple moving average is $74.29 and its 200 day simple moving average is $73.59. The stock has a market capitalization of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. As a group, research analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC increased its position in shares of Insmed by 0.6% during the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after buying an additional 4,560 shares during the period. Capital CS Group LLC bought a new stake in shares of Insmed during the fourth quarter valued at about $586,000. Orion Portfolio Solutions LLC increased its position in shares of Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 9,170 shares during the period. Ally Bridge Group NY LLC increased its position in shares of Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after buying an additional 21,833 shares during the period. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Insmed during the third quarter valued at about $35,322,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on INSM shares. Truist Financial increased their price target on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday. Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company lifted their target price on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.